These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 27623814)

  • 1. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
    Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
    Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Lycke M; Kristjansdottir B; Sundfeldt K
    Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF) improves the sensitivity of CA125 for differentiation of epithelial ovarian cancers from ovarian cysts.
    Robati M; Ghaderi A; Mehraban M; Shafizad A; Nasrolahi H; Mohammadianpanah M
    Arch Gynecol Obstet; 2013 Oct; 288(4):859-65. PubMed ID: 23564055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
    Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
    Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
    Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses.
    Fawzy A; Mohamed MR; Ali MA; Abd El-Magied MH; Helal AM
    Asian Pac J Cancer Prev; 2016; 17(1):323-33. PubMed ID: 26838232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
    Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
    Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma.
    Milivojevic M; Boskovic V; Atanackovic J; Milicevic S; Razic S; Kotlica BK
    Eur J Gynaecol Oncol; 2013; 34(1):83-5. PubMed ID: 23590008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing the Copenhagen Index (CPH-I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery?
    Yoshida A; Derchain SF; Pitta DR; Andrade LA; Sarian LO
    Gynecol Oncol; 2016 Mar; 140(3):481-5. PubMed ID: 26825617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
    Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
    Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of CA19-9 and CA125 in histological subtypes of epithelial ovarian tumors and ovarian endometriosis.
    Nakagawa N; Koda H; Nitta N; Nakahara Y; Uno J; Hashimoto T; Nakahori T; Hasegawa M; Kataoka M
    Acta Med Okayama; 2015; 69(4):227-35. PubMed ID: 26289914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
    Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
    Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of human epididymis protein 4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women.
    Nikolova T; Zivadinovic R; Evtimovska N; Klisarovska V; Stanojevic M; Georgievska J; Nikolova N
    J Obstet Gynaecol Res; 2017 Dec; 43(12):1870-1879. PubMed ID: 29027715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
    Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
    PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.